Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2007 1
2009 1
2010 3
2011 5
2012 2
2013 8
2014 10
2015 3
2016 5
2017 3
2018 4
2019 2
2020 7
2021 6
2022 2
2023 2
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Results by year

Filters applied: . Clear all
Page 1
Therapeutic cancer vaccines.
Schlom J, Hodge JW, Palena C, Tsang KY, Jochems C, Greiner JW, Farsaci B, Madan RA, Heery CR, Gulley JL. Schlom J, et al. Among authors: jochems c. Adv Cancer Res. 2014;121:67-124. doi: 10.1016/B978-0-12-800249-0.00002-0. Adv Cancer Res. 2014. PMID: 24889529 Free PMC article. Review.
Therapeutic Vaccines for HPV-Associated Malignancies.
Smalley Rumfield C, Roller N, Pellom ST, Schlom J, Jochems C. Smalley Rumfield C, et al. Among authors: jochems c. Immunotargets Ther. 2020 Oct 7;9:167-200. doi: 10.2147/ITT.S273327. eCollection 2020. Immunotargets Ther. 2020. PMID: 33117742 Free PMC article. Review.
Combination Therapies for HPV-Associated Malignancies.
Smalley Rumfield C, Schlom J, Jochems C. Smalley Rumfield C, et al. Among authors: jochems c. J Clin Cell Immunol. 2021;12(1):608. Epub 2020 Dec 28. J Clin Cell Immunol. 2021. PMID: 34262794 Free PMC article.
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Lynce F, Mainor C, Donahue RN, Geng X, Jones G, Schlam I, Wang H, Toney NJ, Jochems C, Schlom J, Zeck J, Gallagher C, Nanda R, Graham D, Stringer-Reasor EM, Denduluri N, Collins J, Chitalia A, Tiwari S, Nunes R, Kaltman R, Khoury K, Gatti-Mays M, Tarantino P, Tolaney SM, Swain SM, Pohlmann P, Parsons HA, Isaacs C. Lynce F, et al. Among authors: jochems c. medRxiv [Preprint]. 2023 Dec 4:2023.12.04.23297559. doi: 10.1101/2023.12.04.23297559. medRxiv. 2023. Update in: Nat Commun. 2024 Mar 27;15(1):2691. doi: 10.1038/s41467-024-46961-x. PMID: 38105958 Free PMC article. Updated. Preprint.
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Lynce F, Mainor C, Donahue RN, Geng X, Jones G, Schlam I, Wang H, Toney NJ, Jochems C, Schlom J, Zeck J, Gallagher C, Nanda R, Graham D, Stringer-Reasor EM, Denduluri N, Collins J, Chitalia A, Tiwari S, Nunes R, Kaltman R, Khoury K, Gatti-Mays M, Tarantino P, Tolaney SM, Swain SM, Pohlmann P, Parsons HA, Isaacs C. Lynce F, et al. Among authors: jochems c. Nat Commun. 2024 Mar 27;15(1):2691. doi: 10.1038/s41467-024-46961-x. Nat Commun. 2024. PMID: 38538574 Free PMC article. Clinical Trial.
A Phase I Single-Arm Study of Biweekly NHS-IL12 in Patients With Metastatic Solid Tumors.
Gatti-Mays ME, Tschernia NP, Strauss J, Madan RA, Karzai FH, Bilusic M, Redman J, Sater HA, Floudas CS, Toney NJ, Donahue RN, Jochems C, Marté JL, Francis D, McMahon S, Lamping E, Cordes L, Schlom J, Gulley JL. Gatti-Mays ME, et al. Among authors: jochems c. Oncologist. 2023 Apr 6;28(4):364-e217. doi: 10.1093/oncolo/oyac244. Oncologist. 2023. PMID: 36640137 Free PMC article. Clinical Trial.
Estrogens in rheumatoid arthritis; the immune system and bone.
Islander U, Jochems C, Lagerquist MK, Forsblad-d'Elia H, Carlsten H. Islander U, et al. Among authors: jochems c. Mol Cell Endocrinol. 2011 Mar 15;335(1):14-29. doi: 10.1016/j.mce.2010.05.018. Epub 2010 Jun 8. Mol Cell Endocrinol. 2011. PMID: 20685609 Review.
A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer.
Redman JM, Tsai YT, Weinberg BA, Donahue RN, Gandhy S, Gatti-Mays ME, Abdul Sater H, Bilusic M, Cordes LM, Steinberg SM, Marte JL, Jochems C, Kim SS, Marshall JL, McMahon S, Redmond E, Schlom J, Gulley JL, Strauss J. Redman JM, et al. Among authors: jochems c. Oncologist. 2022 Mar 11;27(3):198-209. doi: 10.1093/oncolo/oyab046. Oncologist. 2022. PMID: 35274710 Free PMC article. Clinical Trial.
59 results